&nbsp;

Mar 2024

Drug

nab-PACLitaxel

Other Name(s): Abraxane®

Quick Link(s):

Dec 2024

Drug

lomustine

Other Name(s): CeeNU®

Quick Link(s):

Aug 2024

Drug

nelarabine

Other Name(s): Atriance®

Quick Link(s):

Apr 2024

Drug

nivolumab

Other Name(s): Opdivo®

Quick Link(s):

Oct 2024

Drug

lanreotide

Other Name(s): Somatuline® Autogel®

Quick Link(s):

Jun 2024

Regimen

LOMU

Cancer Type:

Central Nervous System

Intent: Palliative

Funding:

ODB - General Benefit

lomustine

Drugs Used:

lomustine

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

NPAC(W)

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes

Drugs Used:

nab-PACLitaxel

Quick Link(s):

Regimen Monograph

Dec 2024

Regimen

NIVL

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

NIVL

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab - Advanced or Metastatic Non-Small Cell Lung Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

NIVL

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab - Relapsed Classical Hodgkin Lymphoma (cHL) Post-Autologous Stem Cell Transplant (ASCT) or ASCT Ineligible

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

NIVL

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and No Prior mTOR Inhibitor

New Drug Funding Program

Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and Prior mTOR Inhibitor

Drugs Used: